JP2022524018A - Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 - Google Patents

Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 Download PDF

Info

Publication number
JP2022524018A
JP2022524018A JP2021552750A JP2021552750A JP2022524018A JP 2022524018 A JP2022524018 A JP 2022524018A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2021552750 A JP2021552750 A JP 2021552750A JP 2022524018 A JP2022524018 A JP 2022524018A
Authority
JP
Japan
Prior art keywords
fusion protein
variant
seq
molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021552750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524018A5 (https=
JPWO2020181235A5 (https=
Inventor
ジョン マム，
Original Assignee
デカ バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デカ バイオサイエンシーズ， インコーポレイテッド filed Critical デカ バイオサイエンシーズ， インコーポレイテッド
Publication of JP2022524018A publication Critical patent/JP2022524018A/ja
Publication of JP2022524018A5 publication Critical patent/JP2022524018A5/ja
Publication of JPWO2020181235A5 publication Critical patent/JPWO2020181235A5/ja
Priority to JP2025176328A priority Critical patent/JP2026016505A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552750A 2019-03-06 2020-03-06 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 Withdrawn JP2022524018A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176328A JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962814669P 2019-03-06 2019-03-06
US62/814,669 2019-03-06
US201962899504P 2019-09-12 2019-09-12
US62/899,504 2019-09-12
US202062962332P 2020-01-17 2020-01-17
US62/962,332 2020-01-17
PCT/US2020/021498 WO2020181235A1 (en) 2019-03-06 2020-03-06 Il-10 variant molecules and methods of treating inflammatory disease and oncology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176328A Division JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Publications (3)

Publication Number Publication Date
JP2022524018A true JP2022524018A (ja) 2022-04-27
JP2022524018A5 JP2022524018A5 (https=) 2023-04-26
JPWO2020181235A5 JPWO2020181235A5 (https=) 2023-04-26

Family

ID=72334859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552750A Withdrawn JP2022524018A (ja) 2019-03-06 2020-03-06 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176328A Pending JP2026016505A (ja) 2019-03-06 2025-10-20 Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法

Country Status (7)

Country Link
US (8) US10858412B2 (https=)
EP (1) EP3934681A4 (https=)
JP (2) JP2022524018A (https=)
KR (1) KR20210139312A (https=)
CN (2) CN114072164A (https=)
CA (1) CA3132385A1 (https=)
WO (1) WO2020181235A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CN112898436A (zh) * 2020-10-23 2021-06-04 广州医科大学附属肿瘤医院 一种具有靶向功能的鼠pd1和鼠il-15基因融合蛋白的表达及其应用
KR102792982B1 (ko) * 2021-05-28 2025-04-14 한양대학교 산학협력단 세포투과성 펩티드 및 이의 용도
WO2023078245A1 (zh) * 2021-11-02 2023-05-11 广东菲鹏制药股份有限公司 Il10单体融合蛋白及其应用
JP2024546938A (ja) * 2021-12-13 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
CN118900697A (zh) 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法
CN114632156B (zh) * 2022-05-17 2022-08-16 中国人民解放军军事科学院军事医学研究院 Tim-3在预防、治疗或减轻疼痛中的应用
WO2024097875A1 (en) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
KR20250078792A (ko) * 2023-11-24 2025-06-04 주식회사 메드팩토 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途
CN119613546B (zh) * 2025-02-10 2025-05-13 细胞生态海河实验室 Il-10抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502137A (ja) * 2007-10-30 2011-01-20 フィロゲン エスピーエー 関節リウマチと関連する抗原
JP2012504425A (ja) * 2008-10-02 2012-02-23 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ８６アンタゴニストの多標的結合タンパク質
JP2014519807A (ja) * 2011-04-29 2014-08-21 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート
JP2016500670A (ja) * 2012-10-03 2016-01-14 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
KR20160043927A (ko) 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2017091611A1 (en) * 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
UY37003A (es) * 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502137A (ja) * 2007-10-30 2011-01-20 フィロゲン エスピーエー 関節リウマチと関連する抗原
JP2012504425A (ja) * 2008-10-02 2012-02-23 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ８６アンタゴニストの多標的結合タンパク質
JP2014519807A (ja) * 2011-04-29 2014-08-21 ロシュ グリクアート アーゲー 新規なイムノコンジュゲート
JP2016500670A (ja) * 2012-10-03 2016-01-14 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
JP2017506075A (ja) * 2014-02-06 2017-03-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インターロイキン−１０イムノコンジュゲート

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DING Y ET AL.: "A single amino acid determines the immunostimulatory activity of interleukin 10", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 191, no. 2, JPN6024003690, 17 January 2000 (2000-01-17), pages 213 - 224, ISSN: 0005621330 *
FERCHER CHRISTIAN ET AL.: ""Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immuno", EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 243, no. 2, JPN6024041277, 19 December 2017 (2017-12-19), pages 166 - 183, ISSN: 0005621327 *
JOG NR ET AL.: "Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes", FRONTIERS IN IMMUNOLOGY, vol. 9, no. 2198, JPN6024003688, 9 October 2018 (2018-10-09), pages 1 - 11, ISSN: 0005621328 *
SALEK-ARDAKANI S ET AL.: "Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human m", VIROLOGY, vol. 304, no. 2, JPN6024003689, 2 December 2012 (2012-12-02), pages 342 - 351, ISSN: 0005621329 *
VAZQUEZ-LOMBARDI RODRIGO ET AL.: ""Molecular Engineering of Therapeutic Cytokines"", ANTIBODIES, vol. 2, no. 3, JPN6024041278, 3 July 2013 (2013-07-03), pages 426 - 451, ISSN: 0005437054 *

Also Published As

Publication number Publication date
US10975133B2 (en) 2021-04-13
US10981966B2 (en) 2021-04-20
CN114072164A (zh) 2022-02-18
US20200385435A1 (en) 2020-12-10
US20220106373A1 (en) 2022-04-07
US20200399337A1 (en) 2020-12-24
US20240294591A1 (en) 2024-09-05
KR20210139312A (ko) 2021-11-22
US20210040168A1 (en) 2021-02-11
CN121652287A (zh) 2026-03-13
US20200283488A1 (en) 2020-09-10
JP2026016505A (ja) 2026-02-03
US20200385436A1 (en) 2020-12-10
EP3934681A4 (en) 2023-12-20
US10981965B2 (en) 2021-04-20
US10975134B2 (en) 2021-04-13
CA3132385A1 (en) 2020-09-10
EP3934681A1 (en) 2022-01-12
WO2020181235A1 (en) 2020-09-10
US20200385437A1 (en) 2020-12-10
US10858412B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
JP2022524018A (ja) Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
US12145007B2 (en) Dual cytokine fusion proteins comprising IL-10
JP2024546938A (ja) マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
CN118715239A (zh) 包含多亚基细胞因子的双细胞因子融合蛋白
RU2836849C2 (ru) Вариантные молекулы il-10 и способ лечения злокачественной опухоли

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251020

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20251208